Definiens AG, a leader in advanced image intelligence solutions, today announced that they have entered into an agreement with The Wellcome Trust Sanger Institute at Cambridge, UK to augment their programmes aimed at creating large scale gene expression profiles.
The ‘Atlas of Protein Expression’ and ‘Embryo Gene Expression’ programs at the Wellcome Trust Sanger Institute both aim to produce large scale public databases describing gene and protein expression patterns in the developing embryo and adult tissues. “To achieve these ends we have applied high throughput immunohistochemistry and automated image capture, generating Terabyte scale image databases”, commented Dr Gareth Maslen, Informatics Project Manager at the Wellcome Trust Sanger Institute. “We felt that traditional methods of manual image analysis and annotation were unlikely to cope with the volume and complexity of the data being generated”.
The Wellcome Trust Sanger Institute has chosen to implement Definiens’ image analysis solution Cellenger® to help improve the throughput, analysis and annotation of images generated by these programs.
“We are very delighted to offer a comprehensive and meaningful solution for image analysis with our leading-edge technology and to share our expertise with world renowned research scientists at a prestigious institute such as The Wellcome Trust Sanger Institute,” stated Thomas Heydler, CEO of Definiens AG.
“Our collaboration with The Wellcome Trust Sanger Institute is a major stepping stone for Definiens and we look forward to assist this world-class research centre in successfully incorporating our technology into their research programs.” says Dr Neil Dey, VP of Marketing and Business Development at Definiens.
Commercial terms of the collaboration were not disclosed.
About The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute (www.sanger.ac.uk), which receives the majority of its funding from the Wellcome Trust, was founded in 1992 as the focus for UK sequencing efforts. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms such as mouse and zebrafish, and more than 90 pathogen genomes. In October 2001, new funding was awarded by the Wellcome Trust to support a new range of post-genomic programmes designed to understand the biological function of genes and their relevance to our health. These programmes are built around a Faculty of more than 30 senior researchers.
Definiens is a global leader in providing advanced image intelligence solutions and services that enable its clients to harness all relevant information from digital image to support fast and accurate decision making crucial to its business process. Definiens’ products are built on its platform technology (eCognition) that represents a quantum leap in the realms of digital image analysis. Our products are offered across chosen markets, initially focusing on Earth Observation/Remote Sensing (EO/RS) and Life Sciences. Definiens offers advanced and robust image analysis solutions to accelerate the drug discovery, development, and diagnostics processes in life sciences, and perform satellite and aerial image classification more intelligently, more accurately, and more efficiently than traditional methods. Definiens has customers worldwide in the areas of Life Sciences and Earth Observation/Remote Sensing (EO/RS), including leading companies, academic centers, and government agencies. Founded in 1994 by Nobel Laureate Prof. Dr. Gerd Binnig, Definiens is based in Munich, Germany. For further information regarding the company and its products please visit www.definiens.com.
Definiens AG Andrea Mueller-Beilschmidt,
+49 (0)89 23 11 80-36
Mobile +49 (0)171 76 66 518
Fax +49 (0)89 23 11 80-90